These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 17004890)
1. Inhibition of pro-angiogenic factors by a lipid-rich shark extract. Yuan L; Yoshida M; Davis PF J Med Food; 2006; 9(3):300-6. PubMed ID: 17004890 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of tyrosine phosphorylation of vascular endothelial growth factor receptors in human umbilical vein endothelial cells: a potent anti-angiogenic lipid-rich extract from shark. Yuan L; Ahn IS; Davis PF J Med Food; 2007 Dec; 10(4):657-61. PubMed ID: 18158837 [TBL] [Abstract][Full Text] [Related]
3. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116 [TBL] [Abstract][Full Text] [Related]
4. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF. Jia H; Jezequel S; Löhr M; Shaikh S; Davis D; Soker S; Selwood D; Zachary I Biochem Biophys Res Commun; 2001 Apr; 283(1):164-73. PubMed ID: 11322784 [TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897 [TBL] [Abstract][Full Text] [Related]
9. FGF2 is crucial for the development of bovine luteal endothelial networks in vitro. Woad KJ; Hammond AJ; Hunter M; Mann GE; Hunter MG; Robinson RS Reproduction; 2009 Sep; 138(3):581-8. PubMed ID: 19542253 [TBL] [Abstract][Full Text] [Related]
10. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist. Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells. Deissler HL; Deissler H; Lang GE Br J Ophthalmol; 2011 Aug; 95(8):1151-6. PubMed ID: 21273213 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis. Haspel HC; Scicli GM; McMahon G; Scicli AG Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307 [TBL] [Abstract][Full Text] [Related]
13. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Laschke MW; Elitzsch A; Vollmar B; Vajkoczy P; Menger MD Hum Reprod; 2006 Jan; 21(1):262-8. PubMed ID: 16172144 [TBL] [Abstract][Full Text] [Related]
14. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2. Kernt M; Thiele S; Neubauer AS; Koenig S; Hirneiss C; Haritoglou C; Ulbig MW; Kampik A Retina; 2012 Sep; 32(8):1652-63. PubMed ID: 22466477 [TBL] [Abstract][Full Text] [Related]
15. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364 [TBL] [Abstract][Full Text] [Related]
17. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors. Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903 [TBL] [Abstract][Full Text] [Related]
18. Epigallocatechin-3-gallate inhibits the PDGF-induced VEGF expression in human vascular smooth muscle cells via blocking PDGF receptor and Erk-1/2. Park JS; Kim MH; Chang HJ; Kim KM; Kim SM; Shin BA; Ahn BW; Jung YD Int J Oncol; 2006 Nov; 29(5):1247-52. PubMed ID: 17016658 [TBL] [Abstract][Full Text] [Related]
19. Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis. Jia H; Lohr M; Jezequel S; Davis D; Shaikh S; Selwood D; Zachary I Biochem Biophys Res Commun; 2001 May; 283(2):469-79. PubMed ID: 11327725 [TBL] [Abstract][Full Text] [Related]
20. R-(-)-beta-O-methylsynephrine, a natural product, inhibits VEGF-induced angiogenesis in vitro and in vivo. Kim NH; Pham NB; Quinn RJ; Kwon HJ Biochem Biophys Res Commun; 2010 Aug; 399(1):20-3. PubMed ID: 20643105 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]